Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010-021367-32 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). The doses specified relate to the doses of PEG. Secondary objectives were measured by analysis of a subject diary and self-reported BM data. The secondary objectives included comparisons of PEG+E doses at 24 h for: BM control; relief of gas; relief of bloating; and relief of abdominal discomfort/cramping.
In addition, the proportion of subjects with a BM (without straining and without hard and/or lumpy stool) within the first 24 h of treatment for subjects taking different doses of PEG+E was evaluated for the time to first BM.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PEG + E, 13.125 g | Experimental | Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time |
|
| PEG + E, 26.25 g | Experimental | Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time |
|
| PEG + E, 39.375 g | Experimental | Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430) | Drug | 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration | A successful BM was defined as a BM with no straining or hard/lumpy stools. | From time of study drug treatment up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration | Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool). | From time of study drug administration up to 3 Days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cork | Ireland |
Not provided
| Label | URL |
|---|---|
| Click here to find information about studies related to Bayer Healthcare products conducted in Europe. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | PEG + E 13.125 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as a single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| FG001 | PEG + E 26.25 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| FG002 | PEG + E 39.375 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PEG + E 13.125 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as a single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment |
| BG001 | PEG + E 26.25 g |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration | A successful BM was defined as a BM with no straining or hard/lumpy stools. | Intent-to-Treat (ITT) Population: defined as all participants randomized regardless of whether they had taken study treatment. | Posted | Number | percentage of participants | From time of study drug treatment up to 24 hours |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PEG + E 13.125 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as a single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
Not provided
| ID | Term |
|---|---|
| D003248 | Constipation |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004573 | Electrolytes |
| ID | Term |
|---|---|
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration | A successful BM was defined as a BM with no straining or hard/lumpy stools. | From time of study drug treatment up to 12 hours |
| Mean Visual Analog Scale (VAS) Rating for BM Control | The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group | From time of study drug treatment up to 24 hours |
| Mean VAS Rating for Gas | The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | From time of study drug treatment up to 24 hours |
| Mean VAS Rating for Bloating | The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | From time of study drug treatment up to 24 hours |
| Mean VAS Rating for Abdominal Discomfort/Cramping | The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | From time of study drug treatment up to 24 hours |
| Mean Participant Global Assessment of Treatment | At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective. | From time of study drug administration up to 2 Days |
Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| BG002 | PEG + E 39.375 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
| OG002 | PEG + E 39.375 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. |
|
|
|
| Secondary | Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration | Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool). | Participants in the ITT Population (defined as all participants who were randomized regardless of whether they had taken study treatment) who had a successful bowel movement (no straining or hard/lumpy stools). Participants who reported no successful BMs were censored. | Posted | Number | participants | From time of study drug administration up to 3 Days |
|
|
|
| Secondary | Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration | A successful BM was defined as a BM with no straining or hard/lumpy stools. | Intent-to-Treat (ITT) Population: defined as all participants randomized regardless of whether they had taken study treatment. | Posted | Number | percentage of participants | From time of study drug treatment up to 12 hours |
|
|
|
|
| Secondary | Mean Visual Analog Scale (VAS) Rating for BM Control | The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group | Participants in the ITT Population (defined as all participants who were randomized regardless of whether they had taken study treatment) who had data available. | Posted | Mean | Standard Deviation | mm | From time of study drug treatment up to 24 hours |
|
|
|
|
| Secondary | Mean VAS Rating for Gas | The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | Participants in the ITT Population (defined as all participants who were randomized regardless of whether they had taken study treatment) who had data available. | Posted | Mean | Standard Deviation | mm | From time of study drug treatment up to 24 hours |
|
|
|
|
| Secondary | Mean VAS Rating for Bloating | The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | Participants in the ITT Population (defined as all participants who were randomized regardless of whether they had taken study treatment) who had data available. | Posted | Mean | Standard Deviation | mm | From time of study drug treatment up to 24 hours |
|
|
|
|
| Secondary | Mean VAS Rating for Abdominal Discomfort/Cramping | The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group. | Participants in the ITT Population (defined as all participants who were randomized regardless of whether they had taken study treatment) who had data available. | Posted | Mean | Standard Deviation | mm | From time of study drug treatment up to 24 hours |
|
|
|
|
| Secondary | Mean Participant Global Assessment of Treatment | At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective. | Intent-to-Treat (ITT) Population: defined as all participants randomized regardless of whether they had taken study treatment. | Posted | Mean | Standard Deviation | units on a scale | From time of study drug administration up to 2 Days |
|
|
|
|
| 0 |
| 52 |
| 0 |
| 52 |
| EG001 | PEG + E 26.25 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. | 0 | 51 | 0 | 51 |
| EG002 | PEG + E 39.375 g | Participants received Polyethylene Glycol plus Electrolytes (PEG+E) as three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time on the day of open-label treatment. | 0 | 51 | 0 | 51 |
Schering-Plough HealthCare Products, Inc. reserves all publication and presentation rights.
|
| Successful BM in >1.0 days through 1.5 days |
|
| The treatment success rate was calculated as the number of participants in a treatment group with treatment successes (BM with no straining or hard/lumpy stools) divided by the total number of participants in the treatment group. Treatment success rate was calculated for each dose group along with 95% confidence intervals (CI) based on exact binomial statistics. Treatment success rates were compared between each pair of treatments using an exact 2-sided test (Fisher's). | Fisher Exact | 0.5256 | Treatment Success Rate | 0.157 | 2-Sided | 95 | 0.070 | 0.286 | No | Superiority or Other |
| The treatment success rate was calculated as the number of participants in a treatment group with treatment successes (BM with no straining or hard/lumpy stools) divided by the total number of participants in the treatment group. Treatment success rate was calculated for each dose group along with 95% confidence intervals (CI) based on exact binomial statistics. Treatment success rates were compared between each pair of treatments using an exact 2-sided test (Fisher's). | Fisher Exact | 0.7746 | Treatment Success Rate | 0.118 | 2-Sided | 95 | 0.044 | 0.239 | No | Superiority or Other |
| Logistic regression analysis was performed with treatment success as the dichotomous dependent variable and dose (13.125g, 26.25g, or 39.375 g) as the independent variable. The main effects for the model were tested for significance at the 5% level. The odds of response for the 26.25 g dose level versus the 13.125 g dose level were presented together with the associated 95% confidence intervals. There were no multiplicity adjustments. | Regression, Logistic | Odds Ratio (OR) | 2.233 | 2-Sided | 95 | 0.628 | 7.940 | No | Superiority or Other |
| Logistic regression analysis was performed with treatment success as the dichotomous dependent variable and dose (13.125g, 26.25g, or 39.375 g) as the independent variable. The main effects for the model were tested for significance at the 5% level. The odds of response for the 39.375 g dose level versus the 13.125 g dose level were presented together with the associated 95% confidence intervals. There were no multiplicity adjustments. | Regression, Logistic | Odds Ratio (OR) | 1.600 | 2-Sided | 95 | 0.424 | 6.043 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.706 |
| 2-Sided |
| 95 |
| -9.729 |
| 13.141 |
| No |
| Superiority or Other |
| ANCOVA | 0.2941 | Mean Difference (Final Values) | -6.046 | 2-Sided | 95 | -17.412 | 5.320 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -2.075 |
| 2-Sided |
| 95 |
| -12.693 |
| 8.544 |
| No |
| Superiority or Other |
| ANCOVA | 0.8850 | Mean Difference (Final Values) | -0.772 | 2-Sided | 95 | -11.329 | 9.784 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.245 |
| 2-Sided |
| 95 |
| -11.471 |
| 13.962 |
| No |
| Superiority or Other |
| ANCOVA | 0.0744 | Mean Difference (Final Values) | -11.641 | 2-Sided | 95 | -24.449 | 1.167 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 2.887 |
| 2-Sided |
| 95 |
| -6.765 |
| 12.539 |
| No |
| Superiority or Other |
| ANCOVA | 0.8685 | Mean Difference (Final Values) | -0.803 | 2-Sided | 95 | -10.397 | 8.790 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.139 |
| 2-Sided |
| 95 |
| -0.602 |
| 0.323 |
| No |
| Superiority or Other |
| ANCOVA | 0.4670 | Mean Difference (Final Values) | 0.172 | 2-Sided | 95 | -0.293 | 0.637 | No | Superiority or Other |